Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065557 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis
A Phase 3 study of Ulcerative Colitis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
- 20
- Study locations
NCT02065557 is a Phase 3 study of Ulcerative Colitis that has completed, run by AbbVie. The registered enrollment target is 101 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02065557, a Phase 3 study of Ulcerative Colitis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).
Conditions Studied
Interventions
- BIOLOGICAL Adalimumab
- BIOLOGICAL Placebo
Study Locations (20)
California
- Childrens Hospital LA /ID# 147452 - Los Angeles
- Univ California, San Francisco /ID# 120901 - San Francisco
Georgia
- Emory University Hospital /ID# 121858 - Atlanta
- Children's Ctr Digestive, US /ID# 121855 - Atlanta
Illinois
- University of Chicago /ID# 120904 - Chicago
- Loyola University Medical Ctr /ID# 120900 - Maywood
Massachusetts
- Massachusetts General Hospital /ID# 124551 - Boston
- Boston Childrens Hospital /ID# 147714 - Boston
Minnesota
- Mayo Clinic - Rochester /ID# 121056 - Rochester
- Minnesota Gastroenterology P.A /ID# 120895 - Saint Paul
New York
- North Shore University Hospital /ID# 120905 - New Hyde Park
- Univ Rochester Med Ctr /ID# 127776 - Rochester
Florida
- Arnold Palmer Hosp Children /ID# 120898 - Orlando
Indiana
- Indiana University /ID# 120908 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2014-10-13 |
| Est. Completion | 2020-02-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02065557
The ClinicalTrials.gov registry entry for NCT02065557 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Adalimumab is the first listed.
NCT02065557 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT02065557 about?
NCT02065557 is a clinical study titled "Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis". The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).
What is the current status of trial NCT02065557?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2014-10-13. Estimated completion is 2020-02-07.
What conditions does trial NCT02065557 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT02065557?
The interventions under investigation include: Adalimumab (BIOLOGICAL), Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02065557?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02065557 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.